NEW YORK (GenomeWeb News) — Molecular diagnostics company Source MDx today said it will work with Pfizer to uncover biomarkers linked to response and resistance to certain of the drug giant’s cancer and inflammatory candidate compounds.
As part of the multi-year alliance, the firms will use genomic and RNA transcription profiling to identify inflammation and cancer-related biomarkers in whole blood and circulating rare cells.
Validated biomarkers “will lead to joint commercial opportunities in companion diagnostics,” the companies said.
Source MDx stands to receive an undisclosed equity investment and technology license payment from Pfizer, plus undisclosed R&D funding over the term of the alliance.
Source MDx said it will also retain commercial rights to diagnostic biomarkers discovered and validated during the collaboration.
Financial terms of the alliance were not disclosed.